CareDx (STU:1K9) Moat Score: 6/10 (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1K9 CareDx Inc STU:1K9
73 GF Score
Price €33.00
GF Value €18.75
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CareDx Moat Score?

CareDx STU:1K9 73 Moat Score is 6 as of Jul. 24, 2026. GuruFocus rates STU:1K9 with a GF Score™ of 73/100 and a GF Value™ of €18.75 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, CareDx ranks better than 93.95% on this metric.

CareDx has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

CareDx has Narrow Moat: CareDx has a strong narrow moat due to its proprietary diagnostic tests and established relationships with transplant centers. It benefits from customer loyalty and some pricing power, but faces competition and lacks wide regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes CareDx might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

CareDx  (STU:1K9) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

CareDx Moat Score Related Terms

STU:1K9 vs PSNL, OPK, NEO: Moat Score Comparison

For the Diagnostics & Research subindustry, CareDx's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CareDx Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, CareDx's Moat Score distribution charts can be found below:

* The bar in red indicates where CareDx's Moat Score falls into.


STU:1K9
73GF Score
CareDx Inc STU:1K9
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
CareDx (STU:1K9) has a Moat Score of 6 as of Jul. 24, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, CareDx ranks #13 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 6%.
Is CareDx's Moat Score too high?
CareDx's current Moat Score is 6. Based on the distribution chart, CareDx ranks #13 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, CareDx has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CareDx's Moat Score compare to PSNL and OPK?
According to the Medical Diagnostics & Research industry distribution chart, CareDx ranks #13 out of 215 companies for Moat Score. This places CareDx in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. CareDx's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareDx stock overvalued right now?
Based on GuruFocus' analysis, CareDx (STU:1K9) is currently considered Significantly Overvalued. The stock's GF Value™ is €18.75, compared to a current price of €33.00 — trading 76% above its estimated fair value. The current Moat Score is 6. CareDx's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For CareDx (STU:1K9), the current Moat Score is 6 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CareDx (STU:1K9) Overvalued in 2026?

Based on GuruFocus' analysis, CareDx stock appears to be overvalued. The current stock price of €33.00 is trading 76% above its estimated GF Value™ of €18.75. GuruFocus considers CareDx to be Significantly Overvalued.

Key valuation signals for STU:1K9:

  • Moat Score: 6
  • GF Value™: €18.75 vs. price of €33.00 (76% above fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the STU:1K9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CareDx Business Description

Other Exchanges CDNA:USA
Address 8000 Marina Boulevard, Brisbane, CA, USA, 94005
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
73GF Score

Get the complete analysis for STU:1K9

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.00
Price
€18.75
GF Value